Achieve Life Sciences Reports Q1 2025 Results, Focus on Cytisinicline Program Amid Financial Challenges
Achieve Life Sciences reported a GAAP EPS of -$0.37 for Q1 2025, aligning with expectations, as the company focuses on developing and commercializing its cytisinicline program for nicotine addiction.
2 minutes to read